Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.

The detection of mutant spectra within a population of microorganisms is critical for the management of drug-resistant infections. We performed ultra-deep pyrosequencing to detect minor sequence variants in HIV-1 protease and reverse transcriptase (RT) genes from clinical plasma samples. We estimated empirical error rates from four HIV-1 plasmid clones and used them to develop a statistical approach to distinguish authentic minor variants from sequencing errors in eight clinical samples. Ultra-deep pyrosequencing detected an average of 58 variants per sample compared with an average of eight variants per sample detected by conventional direct-PCR dideoxynucleotide sequencing. In the clinical sample with the largest number of minor sequence variants, all 60 variants present in > or =3% of genomes and 20 of 35 variants present in <3% of genomes were confirmed by limiting dilution sequencing. With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations.

[1]  J. Rothberg,et al.  HIGH-THROUGHPUT, MASSIVELY PARALLEL DNA SEQUENCING TECHNOLOGY FOR THE ERA OF PERSONALIZED MEDICINE , 2007 .

[2]  Fangping Cai,et al.  Detection of minor drug-resistant populations by parallel allele-specific sequencing , 2007, Nature Methods.

[3]  Ingrid A. Beck,et al.  Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency , 2006, Journal of Clinical Microbiology.

[4]  Thomas LaFramboise,et al.  Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.

[5]  J. Mellors,et al.  Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Sarah Palmer,et al.  Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.

[7]  L. Loeb,et al.  The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Tsongalis,et al.  Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[10]  M. Moser,et al.  Quantifying Mixed Populations of Drug-Resistant Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.

[11]  J. Strathern,et al.  Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. , 2005, The Journal of infectious diseases.

[12]  W. Heneine,et al.  Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. , 2005, The Journal of infectious diseases.

[13]  M. Ronaghi,et al.  Genetic variation analyses by Pyrosequencing. , 2005, Mutation research.

[14]  R. Shafer,et al.  Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine , 2005, Journal of acquired immune deficiency syndromes.

[15]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[16]  Ingrid A. Beck,et al.  Comparison of Oligonucleotide Ligation Assay and Consensus Sequencing for Detection of Drug-Resistant Mutants of Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells and Plasma , 2004, Journal of Clinical Microbiology.

[17]  S. Hammer,et al.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.

[18]  R. Shafer,et al.  Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay , 2004, Journal of Virology.

[19]  J. Shendure,et al.  Advanced sequencing technologies: methods and goals , 2004, Nature Reviews Genetics.

[20]  K. Metzner,et al.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.

[21]  H. Agut,et al.  From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. , 2003, Journal of virological methods.

[22]  Jacques Izopet,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.

[23]  B. Larder,et al.  Performance of the Affymetrix GeneChip HIV PRT 440 Platform for Antiretroviral Drug Resistance Genotyping of Human Immunodeficiency Virus Type 1 Clades and Viral Isolates with Length Polymorphisms , 1999, Journal of Clinical Microbiology.

[24]  D. Nickerson,et al.  Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 polGene That Are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine , 1998, Journal of Clinical Microbiology.

[25]  T. Merigan,et al.  Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma , 1997, Journal of clinical microbiology.

[26]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.